Researchers from the Dana-Farber Cancer Institute, Mass General Brigham, and the Broad Institute have identified distinct cellular and genetic differences in colorectal cancer tumors in younger patients. Published in *Nature Medicine*, the study analyzed 189 tumors from patients aged 29 to over 90, using single-nucleus RNA sequencing on more than 850,000 cells. The findings offer key biological clues into why colorectal cancer often behaves more aggressively in younger adults and provide a foundation for developin…
Key points
The elevated presence of supporting connective cells in early-onset tumors is frequently…: The elevated presence of supporting connective cells in early-onset tumors is frequently linked to chemotherapy resistance in solid cancers.
Tracking gradual lifespan shifts rather than relying on strict age cutoffs allowed invest…: Tracking gradual lifespan shifts rather than relying on strict age cutoffs allowed investigators to isolate subtle age-associated tumor dynamics.
Identifying specific cellular patterns and long non-coding RNA activity offers a critical…: Identifying specific cellular patterns and long non-coding RNA activity offers a critical foundation for specialized prevention and targeted therapies.
Sources checked by our analysis pipeline: 1
Study reveals distinct cellular and genetic differences in colorectal cancer in younger patients
Researchers identified age-associated differences in tumor composition and gene activity, creating a foundation for investigating why colorectal cancer can be more aggressive in younger adults
Dana-Farber Cancer Institute researchers, along with Mass General Brigham researchers from the Gene Lay Institute of Immunology and Inflammation, and the Broad Institute, have uncovered biological clues to why colorectal cancer can behave more aggressively in younger people. Published today in Nature Medicine, the study — the largest of its kind — lays a foundation for understanding age-associated differences in colorectal cancer and exploring future treatments.
In the United States, colorectal cancer diagnosis rates among people younger than 50 rose 2.9% per year from 2013 through 2022, according to the American Cancer Society. Its 2026 report identifies colorectal cancer as the leading cause of cancer death in this age group. Younger patients are also more likely to be diagnosed at advanced stages, underscoring the need to better understand the biology of early-onset disease.
"Through Dana-Farber’s Young-Onset Colorectal Cancer Center, we see how…
Republic Polytechnic student Liu Yin Rui earned the institution's 2026 Character Award for creating a modular urine bag hanger tailored for wheelchair users. The innovation was inspired by his volunteer work at AWWA, where he witnessed the daily mobility struggles individuals faced with unsecured medical bags. His achievement highlights how personal resilience following childhood left-sided hemiplegia can translate into practical assistive technology for the wider community.
Medical researchers are evaluating whether genomic therapies can successfully substitute for daily prescription drugs across prevalent conditions like diabetes and heart disease. While existing pharmaceutical regimens can be adjusted or ceased if side effects occur, altering somatic DNA creates irreversible changes that carry unpredictable long-term consequences. Establishing comprehensive safety data remains essential before regulatory bodies can justify deploying these permanent interventions for widely manageab…
Researchers at the RIKEN Pioneering Research Institute in Japan have harnessed the natural carbon monoxide released by tumors to synthesize therapeutic agents strictly within diseased tissue. By shielding metal catalysts inside a protective blood protein, the method confines drug synthesis to targeted areas. This localized reaction offers a pathway to curb the severe, systemic side effects typically caused by conventional chemotherapy treatments.